The phase IIIb PONENTE trial* aims to assess if adults with severe eosinophilic asthma who are treated with benralizumab can safely reduce their doses of oral corticosteroid (OCS) therapy, while still maintaining asthma control.
The anti-interleukin-5 receptor alpha monoclonal antibody benralizumab significantly reduced the rates of severe exacerbations (SevEx) and asthma worsening episodes (AWE) in patients with severe asthma, leading to a reduction in the risk of overall CompEx* events, according to a post hoc analysis of the phase III SIROCCO** and CALIMA*** trials presented at ATS 2019.
Using budesonide/formoterol as needed was as effective as budesonide maintenance therapy in preventing exacerbations but with a lower exposure to ICS among patients with mild asthma, including adolescent patients and regardless of prior treatment used, according to two subgroup analyses of the SYGMA* 1 and 2 studies presented at the ATS 2019 Congress.
Influenza vaccination effectively reduced the risk of influenza-related hospitalizations in patients with chronic obstructive pulmonary disease (COPD) compared with those who were not vaccinated, according to a study presented at ATS 2019.
During the Allergic Rhinitis (AR) Boot Camp held in conjunction with the Bayer Pharmacist Congress 2020, Professor Dr Baharudin Abdullah discussed the management of AR in the primary care setting and the importance of using patient profiles to guide the choice of antihistamines.
Administering daily oral doses of adjunctive perampanel is safe and well tolerated in the treatment of young and older children with focal seizures or generalized tonic‐clonic seizures, in addition to yielding about 40–70 percent reduction in seizure frequency, according to data from the open-label 311 Core Study.
Long‐term treatment with perampanel in the adjunctive setting appears to provide improved seizure control without raising new safety/tolerability signals in patients with epilepsy, particularly those with secondarily generalized seizures at baseline, according to the results of an open-label extension of phase III trials.